Heterocyclic HIV-protease inhibitors

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Virology

Background:

• Current HIV protease inhibitors (HIV PIs) often retain significant peptidic character, impacting pharmacokinetic and pharmacodynamic properties.
• Development of novel chemical entities is crucial for improving treatment efficacy and overcoming drug resistance in HIV-1 infections.

Purpose of the Study:

• To explore the design and development of novel HIV protease inhibitors (HIV PIs) utilizing cyclic scaffolds.
• To investigate how reduced peptidic nature and increased rigidity in inhibitors can enhance interactions with the HIV protease active site, including catalytic aspartic acids and flap region residues.

Main Methods:

• Introduction of cyclic scaffolds to replace traditional dipeptide isosteres in inhibitor design.
• Focus on designing cyclic chemotypes that maintain structural resemblance to peptide substrates while forming distinct interactions with the enzyme.
• Leveraging insights from existing heterocyclic inhibitors like Tipranavir.

Main Results:

• Cyclic scaffolds reduce molecular flexibility, leading to more rigid inhibitor structures.
• These rigid structures are designed to optimize interactions with key residues in the HIV protease active site.
• The approach holds promise for developing novel HIV-1 PIs with improved profiles against multidrug-resistant strains.

Conclusions:

• Cyclic chemotypes represent a promising strategy for designing next-generation HIV protease inhibitors (HIV PIs).
• This approach can lead to compounds with enhanced efficacy and better resistance profiles compared to traditional peptide-based inhibitors.
• The development of rigid, non-peptidic inhibitors is key to advancing HIV therapy.